Zobrazeno 1 - 10
of 213
pro vyhledávání: '"Fang-Shu Ou"'
Autor:
Yan Yang, Fang-Shu Ou, Emil Lou, Joanne Xiu, Hiroyuki Arai, Francesca Battaglin, Heinz-Josef Lenz, Richard M Goldberg, Anthony F Shields, Yasmine Baca, Philip A Philip, John L Marshall, W Michael Korn, Andreas Seeber, Natsuko Kawanishi, Jingyuan Wang, Shivani Soni, Wu Zhang, Shannon M Mumenthaler, Joshua Millstein, Priya Jayachandran, Federico Innocenti, Annika Lenz, Sandra Algaze, Taline Khoukaz, Evanthia Roussos Torres, Jim P Abraham, Benjamin A Weinberg, Alan P Venook
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background The C-C motif chemokine receptor 5 (CCR5)/C-C motif chemokine ligand 5 (CCL5) axis plays a major role in colorectal cancer (CRC). We aimed to characterize the molecular features associated with CCR5/CCL5 expression in CRC and to determine
Externí odkaz:
https://doaj.org/article/0070d43d733f41d1a13e1ef74847bb8d
Autor:
Lynn Symonds, Ming Yu, YuHong Zhang, Fang-Shu Ou, Tyler J. Zemla, Kelly Carter, Monica Bertagnolli, Federico Innocenti, Linda JW Bosch, Gerrit A Meijer, Beatriz Carvalho, William M. Grady, Stacey A. Cohen
Publikováno v:
Epigenetics, Vol 17, Iss 12, Pp 1715-1725 (2022)
Aberrantly methylated genes contribute to the landscape of epigenetic alterations in colorectal adenocarcinoma. The global CpG Island methylator phenotype (CIMP) and individually methylated genes are potential prognostic/predictive biomarkers. Resear
Externí odkaz:
https://doaj.org/article/fedc615c145b49aa9716d591e2847ecb
Autor:
Elizabeth S. Nakasone, Tyler J. Zemla, Ming Yu, She Yu Lin, Fang-Shu Ou, Kelly Carter, Federico Innocenti, Leonard Saltz, William M. Grady, Stacey A. Cohen
Publikováno v:
Epigenetics, Vol 19, Iss 1 (2024)
ABSTRACTWhile epigenomic alterations are common in colorectal cancers (CRC), few epigenomic biomarkers that risk-stratify patients have been identified. We thus sought to determine the potential of ZNF331 promoter hypermethylation (mZNF331) as a prog
Externí odkaz:
https://doaj.org/article/9934e8c678554cc0aff190ec4294bfc1
Autor:
Radia M. Johnson, Xueping Qu, Chu-Fang Lin, Ling-Yuh Huw, Avinashnarayan Venkatanarayan, Ethan Sokol, Fang-Shu Ou, Nnamdi Ihuegbu, Oliver A. Zill, Omar Kabbarah, Lisa Wang, Richard Bourgon, Felipe de Sousa e Melo, Chris Bolen, Anneleen Daemen, Alan P. Venook, Federico Innocenti, Heinz-Josef Lenz, Carlos Bais
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated colorectal cancer tumors, however, its relationship with treatment response remains to be explored. Here, the authors suggest that ARID1A mutations may confer intrinsic
Externí odkaz:
https://doaj.org/article/4488b89ca7bf43bdb1d09041a86d2a0c
Autor:
Fang-Shu Ou, Daniel H. Ahn, Jesse G. Dixon, Axel Grothey, Yiyue Lou, Pashtoon M. Kasi, Joleen M. Hubbard, Eric Van Cutsem, Leonard B. Saltz, Hans-Joachim Schmoll, Richard M. Goldberg, Alan P. Venook, Paulo Hoff, Jean-Yves Douillard, J. Randolph Hecht, Herbert Hurwitz, Cornelis J. A. Punt, Miriam Koopman, Carsten Bokemeyer, Charles S. Fuchs, Eduardo Diaz-Rubio, Niall C. Tebbutt, Chiara Cremolini, Fairooz F. Kabbinavar, Tanios Bekaii-Saab, Benoist Chibaudel, Takayuki Yoshino, John Zalcberg, Richard A. Adams, Aimery de Gramont, Qian Shi
Publikováno v:
Cancers, Vol 15, Iss 16, p 4117 (2023)
Metastatic colorectal cancer (mCRC) is a heterogeneous disease that can evoke discordant responses to therapy among different lesions in individual patients. The Response Evaluation Criteria in Solid Tumors (RECIST) criteria do not take into consider
Externí odkaz:
https://doaj.org/article/ce222f9467be42278701433a1ee37c17
Publikováno v:
Contemporary Clinical Trials Communications, Vol 23, Iss , Pp 100827- (2021)
Introduction: Longitudinal tumor measurements (TM) are commonly recorded in cancer clinical trials of solid tumors. To define patient response to treatment, the Response Evaluation Criteria in Solid Tumors (RECIST) categorizes the otherwise continuou
Externí odkaz:
https://doaj.org/article/d6d34e1f83754cbd87cc35a612e183ca
Autor:
Edoardo Francini, Fang-Shu Ou, Stefano Lazzi, Roberto Petrioli, Andrea G. Multari, Guido Pesola, Luciana Messuti, Elena Colombo, Virginia Livellara, Serena Bazzurri, Sara Cherri, Salvatora T. Miano, Eric G. Wolfe, Steven R. Alberts, Joleen M. Hubbard, Harry H. Yoon, Guido Francini
Publikováno v:
Translational Oncology, Vol 14, Iss 2, Pp 100973- (2021)
Background: High tumor infiltrating lymphocytes (TILs) density was previously shown to be associated with favorable prognosis for patients with colon cancer (CC). However, the impact of TILs on overall survival (OS) of stage II CC patients who receiv
Externí odkaz:
https://doaj.org/article/bb727b9e9ca8480e8ece3bee7ce744b5
Publikováno v:
Contemporary Clinical Trials Communications, Vol 17, Iss , Pp - (2020)
Purpose: Missing data commonly occur in cancer clinical trials (CCT) and may hinder the search for alternative trial endpoints. We consider reasons for missing tumor measurement (TM) data in CCT and how missing TM data are typically handled. We explo
Externí odkaz:
https://doaj.org/article/975608b1cfed44849fd35ce68d122996
Autor:
Edoardo Francini, Fang-Shu Ou, Justin Rhoades, Eric G. Wolfe, Edward P. O’Connor, Gavin Ha, Gregory Gydush, Kaitlin M. Kelleher, Rupal S. Bhatt, Steven P. Balk, Christopher J. Sweeney, Viktor A. Adalsteinsson, Mary-Ellen Taplin, Atish D. Choudhury
Publikováno v:
Cancers, Vol 13, Iss 16, p 4055 (2021)
There are no biomarkers predictive of resistance to docetaxel or cabazitaxel validated for patients with metastatic castration-resistant prostate cancer (mCRPC). We assessed the association between ABCB1 amplification and primary resistance to doceta
Externí odkaz:
https://doaj.org/article/a97a14ca5dce40079676c299d35487e0
Autor:
Matthew H. G. Katz, Fang-Shu Ou, Joseph M. Herman, Syed A. Ahmad, Brian Wolpin, Robert Marsh, Spencer Behr, Qian Shi, Michael Chuong, Lawrence H. Schwartz, Wendy Frankel, Eric Collisson, Eugene J. Koay, JoLeen M. Hubbard, James L. Leenstra, Jeffrey Meyerhardt, Eileen O’Reilly, for the Alliance for Clinical Trials on Oncology
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Borderline resectable pancreatic cancers infiltrate into adjacent vascular structures to an extent that makes an R0 resection unlikely when pancreatectomy is performed de novo. In a pilot study, Alliance for Clinical Trials in Onc
Externí odkaz:
https://doaj.org/article/309dcfbae6bc4c4bbb5d12861352a1a3